Drug Combination in Clinical Cancer Treatments

Author(s): Da-Yong Lu*, Ting-Ren Lu, Nagendra Sastry Yarla, Hong-Ying Wu, Bin Xu, Jian Ding, Hong Zhu

Journal Name: Reviews on Recent Clinical Trials

Volume 12 , Issue 3 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems.

Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on.

Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities.

Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented.

Keywords: Biotherapy, cancer stem cell, drug combination, drug resistance, neoplasm metastasis, personalized cancer therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [202 - 211]
Pages: 10
DOI: 10.2174/1574887112666170803145955
Price: $65

Article Metrics

PDF: 24
PRC: 1